FDA Commissioner Rob Califf (Tom Williams/CQ Roll Call via AP Images)

ICY­MI: FDA com­mis­sion­er calls for more on­shoring of clin­i­cal tri­als

FDA Com­mis­sion­er Robert Califf took to the stage twice in the last 12 hours in San Fran­cis­co, lin­ing up his pri­or­i­ties and dig­ging in on vac­cine mis­in­for­ma­tion, ac­cel­er­at­ed ap­proval re­forms, and a re­newed in­ter­est in on­shoring more clin­i­cal tri­als where com­pa­nies may be try­ing to save mon­ey, par­tic­u­lar­ly in on­col­o­gy.

Tak­ing the stage ear­ly Tues­day at the JP Mor­gan con­fer­ence, Califf told at­ten­dees that the re­cent­ly passed om­nibus spend­ing law is “re­al­ly im­por­tant” for the agency to more quick­ly help spon­sors ver­i­fy or dis­prove the ben­e­fits of ac­cel­er­at­ed ap­provals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.